医疗器械研发生产商Zimmer Biomet Holdings同意收购Monogram Technologies-动脉网

Zimmer Biomet To Lead Orthopedic Robotics With Monogram's AI Tech

benzinga 等信源发布 2025-07-14 10:20



可切换为仅中文







Zimmer Biomet Holdings, Inc

捷迈邦美控股公司

。

ZBH

中北航空

on Monday agreed to acquire

周一同意收购

Monogram Technologies Inc

Monogram 技术公司

。

MGRM

for an upfront payment of $4.04 per share, corresponding to an equity value of approximately $177 million and an enterprise value of

每股预付款4.04美元，相当于约1.77亿美元的股权价值和企业价值

approximately $168 million

大约 1.68 亿美元

。

Monogram common stockholders will also receive a non-tradeable contingent value right (CVR) entitling the holder to receive up to $12.37 per share of common stock in cash if certain product development, regulatory, and revenue milestones are achieved through 2030.

Monogram 的普通股股东还将获得一份不可交易的或有价值权（CVR），如果到 2030 年实现了某些产品开发、监管和收入里程碑，持有者将有权获得每股普通股最高 12.37 美元的现金。

Monogram’s semi- and fully autonomous robotic technologies are expected to add new and differentiated capabilities to expand Zimmer Biomet’s flagship ROSA Robotics platform and broad suite of navigation and enabling technologies.

Monogram的半自动和全自动机器人技术预计将为Zimmer Biomet的旗舰产品ROSA机器人平台及其广泛的导航和辅助技术套件增添新的差异化功能。

Also Read:

另请阅读：

Hip Implant Maker Zimmer Biomet Cuts Annual Profit Forecast On Paragon 28 Deal

髋关节植入物制造商捷迈邦美因Paragon 28交易下调年度利润预测

Monogram has developed a CT-based, semi-autonomous, AI-navigated total knee arthroplasty (TKA) robotic technology, which

Monogram开发了一种基于CT的、半自主的、人工智能导航的全膝关节置换术（TKA）机器人技术，该技术

received FDA 510(k) clearance in March 2025

于2025年3月获得FDA 510(k)许可

and is expected to be commercialized with Zimmer Biomet implants in early 2027.

预计将在 2027 年初与 Zimmer Biomet 植入物一起商业化。

Additionally, Monogram is developing a fully autonomous version of the technology that has the potential to significantly increase safety, efficiency, and outcomes, as well as have additional applications beyond TKA.

此外，Monogram 正在开发该技术的全自主版本，这一版本有潜力显著提高安全性和效率，并改善手术效果，同时在全膝关节置换术（TKA）之外还有其他应用。

Upon closing the proposed transaction, Zimmer Biomet expects to have a clear pathway to become the first and only orthopedics company to offer a fully

在完成拟议的交易后，Zimmer Biomet有望成为首家且唯一一家提供全面解决方案的骨科公司。

autonomous surgical robot

自主手术机器人

。

“Monogram’s technology is a major leap forward, demonstrating our commitment to becoming the boldest and broadest innovator in surgical robotics and navigation,” said

“Monogram的技术是一次重大的飞跃，表明了我们致力于成为手术机器人和导航领域最大胆、最广泛的创新者的决心，”

Ivan Tornos

伊万·托诺斯

, Chairman, President, and Chief Executive Officer of Zimmer Biomet. “…Zimmer Biomet has the potential to become the first company to deliver fully autonomous capabilities and redefine both the standard of care and the future of orthopedic surgery.”

，Zimmer Biomet董事长、总裁兼首席执行官。“……Zimmer Biomet有潜力成为首家提供完全自主能力的公司，并重新定义护理标准和骨科手术的未来。”

The ROSA platform, the cornerstone of Zimmer Biomet’s robotics offering, is rapidly approaching 2,000 installations worldwide.

Zimmer Biomet机器人技术的核心——ROSA平台，正在迅速接近全球2000台的安装量。

Zimmer Biomet is investing in an R&D pipeline that will produce several new products and software applications between now and 2027.

Zimmer Biomet正在投资一个研发管道，将在现在到2027年之间生产多个新产品和软件应用程序。

Trending Investment Opportunities

投资机会趋势

Arrived

到达

Buy shares of homes and vacation rentals for as little as $100.

只需 100 美元，即可购买房屋和度假租赁的股份。

Get Started

开始使用

WiserAdvisor

智慧顾问

Get matched with a trusted, local financial advisor for free.

免费匹配值得信赖的本地财务顾问。

Get Started

开始使用

Point.com

点 com

Tap into your home's equity to consolidate debt or fund a renovation.

利用您房屋的净值来合并债务或为装修提供资金。

Get Started

开始使用

Robinhood

罗宾汉

Move your 401k to Robinhood and get a 3% match on deposits.

将您的401k账户转移到Robinhood，并获得存款3%的匹配奖励。

Get Started

开始使用

This includes ROSA Knee with OptimiZe, which has been submitted to the FDA, and 510(k) clearance is anticipated later this year, as well as ROSA Posterior Hip and the full commercial launch of ROSA Shoulder.

这包括已提交FDA的ROSA Knee with OptimiZe，预计今年晚些时候将获得510(k)许可，以及ROSA Posterior Hip和ROSA Shoulder的全面商业化推出。

Zimmer Biomet plans to fund the proposed transaction using cash on the balance sheet and other available debt financing sources.

Zimmer Biomet计划使用资产负债表上的现金和其他可用的债务融资来源为拟议的交易提供资金。

Zimmer Biomet believes this proposed transaction and the CVR structure are compelling from a strategic and financial standpoint. The acquisition of Monogram further strengthens Zimmer Biomet’s robotics capabilities.

Zimmer Biomet认为，从战略和财务的角度来看，这项拟议的交易和CVR结构非常有吸引力。收购Monogram将进一步增强Zimmer Biomet的机器人技术能力。

Zimmer Biomet expects the acquisition will contribute to revenue growth in 2027 and beyond by improving the company’s robotic knee adoption in the U.S., increasing the share of wallet through reaching new customers with a broader product range, and expanding the company’s industry-leading global knee offerings..

Zimmer Biomet预计，此次收购将通过提升公司在美国的机器人膝关节应用、通过更广泛的产品范围接触新客户来增加钱包份额，以及扩大公司行业领先的全球膝关节产品供应，从而为2027年及以后的收入增长做出贡献。

Zimmer Biomet anticipates the acquisition will be neutral to adjusted earnings per share in 2025, 2026, and 2027 and accretive in 2028 and beyond.

Zimmer Biomet预计，此次收购将对2025年、2026年和2027年的调整后每股收益保持中性，并在2028年及以后产生增值。

Additionally, the transaction is projected to generate a high-single-digit return on invested capital (ROIC) by year five, with an increasing contribution thereafter.

此外，预计到第五年，该交易将实现高个位数的投资资本回报率 (ROIC)，并且此后贡献将持续增加。

Price Action:

价格行为：

MGRM stock is up 60.2% at $5.27, and ZBH stock is up 0.09% at $93.87 at last check Monday.

周一最后一次检查时，MGRM股票上涨60.2%，达到5.27美元，ZBH股票上涨0.09%，达到93.87美元。

加载中...